Genentech Acquires aFraxis for $187,500,000
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=380e6c9b-72ff-4c13-b48e-acfc9115e51e&Preview=1 - Date
1/31/2013 - Company Name
aFraxis - Mailing Address
11099 N Torrey Pines Rd La Jolla, CA 92037 - Company Description
Afraxis is discovering and developing drugs to treat diseases of the central nervous system, including schizophrenia, Alzheimer’s disease, Fragile X syndrome and autism spectrum disorders. Recent scientific discoveries have linked these disorders to underlying defects in the development and function of specialized structures of the neural synapse, called dendritic spines. - Website
http://www.Afraxis.com - Transaction Type
M&A - Transaction Amount
$187,500,000 - Transaction Round
- Proceeds Purposes
- M&A Terms
Under the terms of the agreement, Genentech willhave exclusive, worldwide rights to develop and commercialize Afraxis’proprietary compounds. Afraxis is eligible to receive upfront, research,development and commercialization milestone payments, together totaling up to $187.5 million.
